Brief: ABL Bio Announces Publication Of Preclinical Data Demonstrating Safety And Efficacy Of Abl503/Tj-L14b, A Novel Anti-Pd-L1 X 4-1Bb Bispecific Antibody
09/07/2021 16:39
July 9 (Reuters) - ABL Bio Inc 298380.KQ :
* ABL BIO ANNOUNCES PUBLICATION OF PRECLINICAL DATA
DEMONSTRATING
SAFETY AND EFFICACY OF ABL503/TJ-L14B, A NOVEL ANTI-PD-L1 X
4-1BB BISPECIFIC ANTIBODY
* ABL BIO INC - ABL503/TJ-L14B DEMONSTRATES STRONGER
ANTI-TUMOR
EFFICACY THAN ANTI-PD-L1 OR ANTI-4-1BB MONOTHERAPY AS WELL AS A
GOOD SAFETY PROFILE
Source text for Eikon: urn:newsml:reuters.com:*:nPrebMP2fa
Further company coverage: 298380.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABL Bio
See all newsBrief: Abl Bio Inc - Raises 37.7 Billion Won Worth Of New Shares
Brief: Abl Bio Announces Grabody-B Brain Delivery Platform License Agreement With GSK To Develop Novel Medicines For Neurodegenerative Diseases
Brief: Abl Bio Inc Signs Agreement With Intocell Inc To Use Its Antibody-Drug Conjugate Tech In Product Development
Brief: I-Mab And Abl Bio Announce Latest Updates Of Pd-L1 And 4-1BB Bispecific Antibody TJ-L14B/ABL503
Brief: Abl Bio To Acquire Real Estate Worth 65 Billion Won